Lansforsakringar Fondforvaltning AB publ Has $86.71 Million Stock Position in Boston Scientific Corporation $BSX

Lansforsakringar Fondforvaltning AB publ trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 0.9% in the first quarter, Holdings Channel.com reports. The firm owned 859,556 shares of the medical equipment provider’s stock after selling 7,527 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in Boston Scientific were worth $86,712,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Truvestments Capital LLC raised its position in Boston Scientific by 162.4% during the first quarter. Truvestments Capital LLC now owns 1,522 shares of the medical equipment provider’s stock valued at $154,000 after acquiring an additional 942 shares in the last quarter. B. Metzler seel. Sohn & Co. AG raised its position in Boston Scientific by 1.6% during the first quarter. B. Metzler seel. Sohn & Co. AG now owns 229,394 shares of the medical equipment provider’s stock valued at $23,141,000 after acquiring an additional 3,683 shares in the last quarter. Delta Investment Management LLC bought a new position in Boston Scientific during the first quarter valued at approximately $280,000. Guggenheim Capital LLC raised its position in Boston Scientific by 8.2% during the first quarter. Guggenheim Capital LLC now owns 127,869 shares of the medical equipment provider’s stock valued at $12,899,000 after acquiring an additional 9,678 shares in the last quarter. Finally, CreativeOne Wealth LLC raised its position in shares of Boston Scientific by 36.1% in the first quarter. CreativeOne Wealth LLC now owns 7,679 shares of the medical equipment provider’s stock valued at $775,000 after purchasing an additional 2,037 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, May 16th. Robert W. Baird lifted their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Oppenheimer lifted their price target on shares of Boston Scientific from $110.00 to $118.00 and gave the company a “market perform” rating in a research report on Thursday, July 24th. Raymond James Financial raised their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Boston Scientific in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $117.50.

Insiders Place Their Bets

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock valued at $35,976,603 over the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.4%

Shares of NYSE BSX opened at $105.94 on Thursday. The stock has a market cap of $156.98 billion, a PE ratio of 63.06, a PEG ratio of 2.56 and a beta of 0.66. The business has a fifty day moving average of $104.36 and a two-hundred day moving average of $102.18. Boston Scientific Corporation has a 52-week low of $79.03 and a 52-week high of $108.94. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the business posted $0.62 earnings per share. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.